As of care and financial perspectives, liver biopsy is not possible to be done in each patient suffering from NAFLD.7 Due to significant rise in the prevalence of NAFLD in concurrence with the remarkable research works for making novel therapies for patients, non-invasive, appropriate and dependable serum biomarkers are really required.4 It is noticeable that the laboratory tests done in routine for the assessment of subjects assumed to be NAFLD comprises of a long list of liver biomarkers like serum ALT, AST, alkaline phosphatase(ALP), and gamma-glutamyl-transpeptidase. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.